摘要
目的探讨术前新辅助化疗对食管癌患者肿瘤标志物及Ki-67水平的影响。方法根据是否采用新辅助化疗将80例食管癌患者分为新辅助化疗组(n=41,新辅助化疗后进行手术治疗)和常规组(n=39,常规检查后进行手术治疗)。比较两组患者的肿瘤标志物[鳞状细胞癌抗原(SCCA)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]水平、Ki-67表达情况、肿瘤切除情况、并发症发生情况,记录新辅助化疗组患者的化疗疗效。结果术后,两组患者SCCA、CEA、CA19-9水平均低于本组治疗前,新辅助化疗组患者SCCA、CEA、CA19-9水平均低于常规组,差异均有统计学意义(P﹤0.05)。术后,新辅助化疗组患者Ki-67低表达率高于常规组,差异有统计学意义(P﹤0.05)。两组患者R0切除率和并发症总发生率比较,差异均无统计学意义(P﹥0.05)。新辅助化疗组患者疾病控制率为92.68%(38/41)。结论术前新辅助化疗对食管癌患者具有较好的治疗效果,能够降低肿瘤标志物和Ki-67水平,且不会增加并发症。
Objective To explore the influence of preoperative neoadjuvant chemotherapy on the levels of tumor markers and Ki-67 in patients with esophageal cancer.Method Eighty patients with esophageal cancer were divided into the neoadjuvant chemotherapy group(n=41,surgical treatment after neoadjuvant chemotherapy)and the conventional group(n=39,surgical treatment after routine examination)based on whether neoadjuvant chemotherapy was adopted.The levels of tumor markers[squamous cell carcinoma antigen(SCCA),carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)],the expression of Ki-67,tumor resection,and the occurrence of complications were compared between the two groups,and the chemotherapy efficacy in the neoadjuvant chemotherapy group was recorded.Result After the operation,the levels of SCCA,CEA and CA19-9 in both groups were lower than those before treatment,the levels of SCCA,CEA and CA19-9 in the neoadjuvant chemotherapy group were lower than those in the conventional group,and the differences were statistically significant(P<0.05).After the operation,the low expression rate of Ki-67 in the neoadjuvant chemotherapy group was higher than that in the conventional group,and the difference was statistically significant(P<0.05).There were no statistically significant differences in R0 resection rate and total incidence of complications between the two groups(P>0.05).The disease control rate of the neoadjuvant chemotherapy group was 92.68%(38/41).Conclusion Preoperative neoadjuvant chemotherapy has a good therapeutic effect on patients with esophageal cancer.It can reduce tumor markers and Ki-67 levels without increasing complications.
作者
侯露
张进
杨宸
龙勇
冯超
葛晓晴
HOU Lu;ZHANG Jin;YANG Chen;LONG Yong;FENG Chao;GE Xiaoqing(Department of Thoracic Surgery,the Second Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,He’nan,China)
出处
《癌症进展》
2025年第18期2205-2207,2215,共4页
Oncology Progress
基金
河南省医学科技攻关计划联合共建项目(LHGJ20220449)。
关键词
术前新辅助化疗
食管癌
肿瘤标志物
KI-67
preoperative neoadjuvant chemotherapy
esophageal cancer
tumor marker
Ki-67
